Table 2.

Therapy studies evaluating the clinical response of CBD (cannabidiol) in animals and patients with different neurological conditions. The table includes study designs, subjects, treatments, and outcomes.

Study	Study design	Subjects	Treatment	Outcome	Ref
1	Randomized controlled trial	50 patients with epilepsy	CBD oil (300 mg/day)	Significant reduction in seizure frequency	[27]
2	Double-blind, placebo-controlled trial	100 patients with multiple sclerosis	CBD capsules (10 mg/day)	Improved muscle spasticity and pain relief	[83]
3	Preclinical study (rat model)	Rats with neuropathic pain	CBD injection (5 mg/kg)	Reduced pain sensitivity and inflammation	[84]
4	Case series	10 children with autism spectrum disorder	CBD oral solution (20 mg/kg/day)	Improved social communication and reduced anxiety	[85]
5	Retrospective study	200 patients with Parkinson's disease	CBD tincture (20 mg/day)	Decreased tremors and improved sleep quality	[86]
6	Pilot study	30 patients with posttraumatic stress disorder (PTSD)	CBD vaporization (30 mg/day)	Reduced PTSD symptom severity	[87]
7	Preclinical study (mouse model)	Mice with Alzheimer's disease	CBD treatment (10 mg/kg/day)	Improved cognitive function and reduced neuroinflammation	[88]
8	Open-label trial	50 patients with chronic pain	CBD transdermal patch (30 mg/day)	Reduced pain intensity and improved quality of life	[89]
9	Prospective cohort study	100 children with the Dravet syndrome	CBD oral solution (20 mg/kg/day)	Decreased seizure frequency and improved behaviour	[90]
10	Cross-sectional study	300 patients with anxiety disorders	CBD oil (25 mg/day)	Reduced anxiety symptoms and improved mood	[20]
11	Preclinical study (rat model)	Rats with spinal cord injury	CBD administration (10 mg/kg/day)	Improved motor function recovery and reduced inflammation	[91]
12	Randomized controlled trial	60 patients with schizophrenia	CBD capsules (600 mg/day)	Reduced psychotic symptoms and improved cognitive function	[92]
13	Case-control study	50 patients with Huntington's disease	CBD oil (15 mg/kg/day)	Decreased chorea movements and improved quality of life	[65]
14	Preclinical study (dog model)	Dogs with osteoarthritis	CBD-infused treats (5 mg/kg/day)	Decreased pain and improved mobility	[93]
15	Double-blind, placebo-controlled trial	80 patients with fibromyalgia	CBD gel (100 mg/day)	Reduced pain sensitivity and improved sleep quality	[94]
16	Case series	10 patients with the Tourette syndrome	CBD oral solution (10 mg/kg/day)	Decreased tics and improved tic-related impairment	[95]
17	Retrospective study	200 patients with epilepsy	CBD oil (20 mg/kg/day)	Reduced seizure frequency and improved quality of life	[27]
18	Preclinical study (mouse model)	Mice with amyotrophic lateral sclerosis (ALS)	CBD treatment (5 mg/kg/day)	Delayed disease progression and increased motor function	[22]
19	Randomized controlled trial	50 patients with social anxiety disorder	CBD capsules (300 mg/day)	Reduced anxiety symptoms and improved social interaction	[58]
20	Cross-sectional study	300 patients with migraine	CBD oil (25 mg/day)	Reduced migraine frequency and severity	[96]
21	Open-label trial	30 patients with attention deficit hyperactivity disorder (ADHD)	CBD oral solution (20 mg/kg/day)	Improved ADHD symptoms and reduced impulsivity	[97]
22	Prospective cohort study	100 patients with traumatic brain injury	CBD tincture (25 mg/day)	Improved cognitive function and reduced neuroinflammation	[98]
23	Case-control study	50 patients with multiple system atrophy	CBD oil (15 mg/kg/day)	Decreased autonomic symptoms and improved quality of life	[99]
24	Preclinical study (rat model)	Rats with poststroke neuroinflammation	CBD treatment (5 mg/kg/day)	Reduced neuroinflammation and improved motor recovery	[87]
25	Double-blind, placebo-controlled trial	80 patients with anxiety-related sleep disorders	CBD capsules (50 mg/day)	Improved sleep quality and reduced anxiety	[100]